NS-229 is an investigational selective Janus kinase 1 inhibitor designed to prevent tissue damage caused by EGPA by suppressing immune cell activation.

NS Pharma, a unit of Nippon Shinyaku (OTCPK:NPNKF), said on Monday that the U.S. FDA has granted orphan drug designation to ...

1) Bell, CF., Lau, M., Shen, Q. Clinical and Economic Characteristics of Patients Diagnosed with Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly Churg-Strauss Syndrome) in the United ...

A real-life study suggests that stepping down mepolizumab dosage in EGPA patients in remission is effective, with no asthma ...

Results of the study showed that 51.1% of benralizumab-treated patients compared with 45.4% of mepolizumab-treated patients attained a complete or partial response at 3 months. Notably, the complete ...

Long-term treatment with mepolizumab, an interleukin-5 inhibitor, demonstrates a favorable safety profile and sustained corticosteroid-sparing benefits among patients with eosinophilic granulomatosis ...